Marc Lichtenfeld

Marc Lichtenfeld is the Chief Income Strategist of The Oxford Club and the Senior Editor of The Oxford Income Letter, where he runs the Instant Income Portfolio, Compound Income Portfolio and Retirement Catch-Up/High Yield Portfolio. Marc is also the editor of Dividend Multiplier, Oxford Systems Trader and Lightning Trend Trader.

Also seen on:

As seen on Fox Business, Bloomberg and CNBC

Latest Episode

The Unconventional Way to Generate Income Using Real Estate w/ Property Consultant and Bryan Chavis

 Download

Today’s real estate market is hot.  And in a hot market, it can be challenging to find value. But there is a way to generate solid, reliable income, without flipping houses… And according to this week’s guest, real estate expert Bryan Chavis, it’s a strategy anyone can begin using today. With it, you can generate […]


Recent Episodes

Crowdfunding Opportunities Takeoff in 2017 w/ Private Equity Expert and Early Investing Founder, Adam Sharp

Marc’s just returned from JP Morgan’s 35th annual Healthcare Conference in San Francisco. And in this week’s episode, he’s covering all the details…from groundbreaking new medical technologies, to political sentiment, to insider meetings, and new drug announcements…Marc’s got all the exciting details. Then, he sits down with private equity expert and Early Investing Founder, Adam […]

View Episode

The 2017 Bond Market Forecast w/ Oxford Club Bond Strategist Steve McDonald

Rising interest rates indicate that the Fed’s regaining confidence in the US economy. But, tightening monetary policy can have an adverse affect on fixed income investments, as rising rates hurt bond values. As a result, it’s more important than ever to understand the role of bonds in a diversified portfolio, and where you can find […]

View Episode

Immunotherapy Expert, Brad Loncar, Reveals Biotech Forecast for 2017

Our nation’s top biotech insiders are gathering at JP Morgan’s 35th annual Healthcare Conference in San Francisco next week. I’ll be at the invitation-only event, which draws thousands of top fund mangers, analysts, investment bankers, and drug company CEOs together for an exclusive look at the most promising medical breakthroughs tee’d up for the coming year. […]

View Episode